ArticleTrials2024

Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.

Simron Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.